2seventy bio (TSVT) Scheduled to Post Earnings on Tuesday

2seventy bio (NASDAQ:TSVT - Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.

2seventy bio (NASDAQ:TSVT - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. 2seventy bio had a negative net margin of 354.16% and a negative return on equity of 66.01%. The company had revenue of $8.97 million during the quarter, compared to analyst estimates of $11.43 million. On average, analysts expect 2seventy bio to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

2seventy bio Trading Up 4.2 %

Shares of TSVT stock traded up $0.19 during mid-day trading on Tuesday, reaching $4.70. The stock had a trading volume of 268,183 shares, compared to its average volume of 771,633. The firm has a market capitalization of $242.05 million, a PE ratio of -1.53 and a beta of 1.78. The stock's 50-day moving average price is $4.75 and its two-hundred day moving average price is $4.50. 2seventy bio has a 52-week low of $1.53 and a 52-week high of $6.40.

Insiders Place Their Bets

In other news, insider Jessica Snow sold 7,816 shares of 2seventy bio stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $4.32, for a total value of $33,765.12. Following the completion of the transaction, the insider now owns 156,330 shares of the company's stock, valued at $675,345.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.20% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lowered their target price on 2seventy bio from $7.00 to $6.00 and set an "equal weight" rating for the company in a research note on Monday, July 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $9.00.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.